AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?
This article was originally published in The Pink Sheet Daily
Executive Summary
With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.
You may also be interested in...
Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light
The latest drug development news and highlights from our US FDA Performance Tracker.
AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon
AstraZeneca paid $95m to Swedish Orphan Biovitrum for the voucher, which it could use to expedite the FDA review of roxadustat or trastuzumab deruxtecan.
Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate
The latest drug development news and highlights from our US FDA Performance Tracker.